RIL
LYEL icon

Rothschild Investment LLC’s Lyell Immunopharma LYEL Stock Holding History

Rothschild Investment LLC’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3
Closed -$73 – 2948
2024
Q2 		$73 Buy
+3
New +$143 ﹤0.01% 2775

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rothschild Investment LLC's LYEL Position: Q3 2024 in Review

Rothschild Investment LLC sold out of Lyell Immunopharma (LYEL) in Q3 2024, closing a stake of 3 shares — an estimated $73 sold.

Rothschild Investment LLC first reported a position in LYEL in Q2 2024 and held it in 1 quarter. The position peaked at $73 in Q2 2024. 117 funds tracked by Wall St. Rank hold LYEL as of Q3 2024.

  • Rothschild Investment LLC reported no remaining Lyell Immunopharma position as of Q3 2024 after selling out during the quarter.
  • Rothschild Investment LLC sold 3 Lyell Immunopharma shares in Q3 2024, an estimated $73.
  • Rothschild Investment LLC first reported a position in Lyell Immunopharma in Q2 2024 and held it in 1 quarter.
  • Rothschild Investment LLC's Lyell Immunopharma position peaked at $73 in Q2 2024.
  • 117 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2024.

Based on Rothschild Investment LLC's 13F filing for Q3 2024, filed 18 Oct 2024.